PROTAC PEG

AxisPharm provides high purity PROTAC PEG reagents (linkers) with various active groups, such as azide, acid, amine, etc.
The design of Proteolysis Targeting Chimera (PROTACs) is a powerful small molecule approach for inducing protein degradation for anticancer therapy. PROTACs conjugate a target warhead to an E3 ubiquitin ligase ligand via a linker. To further empower the PROTAC study, AxisPharm are developing a series of PROTAC linker to accelerate our customers’  R&D effort.